MedTrace Logo

Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism

NCT02132689 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-19

No results posted yet for this study

Summary

Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.

Conditions

Interventions

DRUG

Actilyse (Thrombolytic therapy)

DRUG

Heparine (Standard anticoagulation therapy)

Sponsors & Collaborators

  • Municipal Hospital Ostrava Fifejdy

    collaborator UNKNOWN

  • Silesian Hospital Opava

    collaborator UNKNOWN

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Radovan Stancik, MD · Department of Cardiology, University Hospital Ostrava

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-05-31
Completion
2015-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02132689 on ClinicalTrials.gov